Literature DB >> 18751439

Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.

Hisamitsu Ide1, Mitsuko Yasuda, Kojiro Nishio, Keisuke Saito, Shuji Isotani, Yutaka Kamiyama, Satoru Muto, Shigeo Horie.   

Abstract

BACKGROUND: A screening method that focuses on the early detection of high-grade prostate cancer is required. In this study, two sets of nomograms were developed, one to predict the presence of prostate cancer, and the other to predict the presence of high-grade prostate cancer (defined as Gleason Score > or =7). PATIENTS AND METHODS: Prostate biopsies were obtained from 396 men with an abnormal serum level of prostate-specific antigen (PSA). Using factors including age, PSA, follicle stimulating hormone (FSH), serum teststerone level and prostate volume of the transitional zone (TZ), nomograms were created that incorporated these factors. External validations were performed involving 174 males, including 103 normal and 71 prostate cancer cases from our institution.
RESULTS: Out of the 396 patients referred for prostate biopsy, 146 were found to have prostate cancer. On logistic regression analysis, age, PSA, prostate volume of the TZ and FSH were significant predictors of prostate cancer, while serum PSA, and testosterone levels were significant predictors of high-grade prostate cancer. The pretreatment testosterone level was found to be a significant biomarker for predicting the pathological features.
CONCLUSION: The testosterone level might be a useful biomarker to be included in conventional PSA screening programs to further improve the efficacy of detecting potentially lethal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18751439

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

Review 2.  Random biopsy: when, how many and where to take the cores?

Authors:  Vincenzo Scattoni; Carmen Maccagnano; Umberto Capitanio; Andrea Gallina; Alberto Briganti; Francesco Montorsi
Journal:  World J Urol       Date:  2014-06-08       Impact factor: 4.226

3.  Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.

Authors:  Dylan Hoare; Thomas A A Skinner; Angela Black; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

4.  Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer.

Authors:  Huakang Tu; Jian Gu; Qing H Meng; Jeri Kim; Sara Strom; John W Davis; Yonggang He; Elizabeth A Wagar; Timothy C Thompson; Christopher J Logothetis; Xifeng Wu
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

5.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

6.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

7.  Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer.

Authors:  Hisamitsu Ide; Yuichi Terado; Kentaro Sakamaki; Masahiro Inoue; Akiko Nakajima; Yan Lu; Schinichi Hisasue; Raizo Yamaguchi; Satoru Muto; Shigeo Horie
Journal:  Prostate Int       Date:  2013-09-27

8.  Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume).

Authors:  Antonio B Porcaro; Aldo Petrozziello; Matteo Brunelli; Filippo Migliorini; Giovanni Cacciamani; Davide De Marchi; Nicolo' de Luyk; Irene Tamanini; Beatrice Caruso; Maria A Cerruto; Claudio Ghimenton; Walter Artibani
Journal:  Asian J Urol       Date:  2015-11-30

9.  Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone.

Authors:  Naoko Akitake; Masaki Shiota; Hirofumi Obata; Ario Takeuchi; Eiji Kashiwagi; Kenjiro Imada; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Masatoshi Eto
Journal:  Prostate Int       Date:  2017-11-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.